Isomorphic Labs, a spinout from DeepMind, has raised $2.1 billion in new funding to advance its artificial intelligence platform for drug design.
The company aims to leverage AI to accelerate the discovery and development of novel therapeutics, a sector that has seen increasing interest from both private and institutional investors.
The funding round underscores a broader trend of capital flowing into AI applications within the life sciences.
Recent reports indicate that other AI-focused biotech firms, such as ineffable Intelligence, have also secured significant backing, signaling a shift in how pharmaceutical innovation is being financed and executed.
This development aligns with a surge in corporate and academic emphasis on AI in healthcare.
For instance, Nvidia CEO Jensen Huang recently highlighted the importance of AI in his commencement speech at Carnegie Mellon University, reinforcing the industry's growing reliance on machine learning for scientific breakthroughs.